Loading…

RevvityRVTYCompetitor analysis, valuation and peers

United States · USD·Health Care›Medical Specialties

Life-sciences and diagnostics company (renamed from PerkinElmer in 2023) providing reagents, instruments and software for research and diagnostics.

Momentum leader 94
Mkt cap
$17.0B
US dollars, full cap
Free float
100%
of shares outstanding
$/day
$286M
20-day average traded
Fwd P/E
26.2×
forward earnings
ROIC−WACC
-5.7 pp
WACC 9.8%
Hurdle
+32 pp
Req g minus delivered
Official | Implied
BBB / BBB
agencies · bond market
Next earnings
78 days
4 Feb 2027
Close · USD$152.43
1D+3.1%
1W-3.7%
1M-2.3%
3M+22.8%
6M+60.8%
YTD+57.8%
1Y+67.6%
ATR %4.7%
Beta1.16
52w lowhigh11.2% off high

What Revvity does

Life-sciences and diagnostics company (renamed from PerkinElmer in 2023) providing reagents, instruments and software for research and diagnostics.

Sells instruments once and then keeps selling the reagents, assay kits and consumables they need, a pattern that repeats across research labs and diagnostic laboratories, with a software unit alongside. It rebranded from PerkinElmer in 2023 after selling its food and environmental testing business, having bought BioLegend in 2021 to enlarge its research reagents side.

Products and services

  • Life Sciences (reagents, genomics/proteomics tools)
  • Diagnostics (newborn screening, immunodiagnostics)
  • Software/informatics

Customers

  • Pharma/biotech companies
  • Academic/government labs
  • Newborn screening/clinical labs

Where it sits in the supply chain

  • Healthcare/Life Sciences
  • Life science tools & diagnostics
  • Reagents, instruments, software

What could go right

  • Diagnostics/reagent recurring-revenue growth
  • Applied genomics market expansion

What could go wrong

  • Biotech/academic funding cycle sensitivity
  • China market softness

Moat: narrow (installed base, switching costs, brand). Established newborn-screening and reagent franchises with recurring, workflow-embedded consumables.

Headquarters: Waltham, Massachusetts, USA · Founded: 1937 · Employees: 11,000

Named competitors

Revvity at a glance

Size Revvity (RVTY) is a United States Health Care company (Medical Specialties) with a market value of $17.0B, the 547th largest of 3,085 United States companies the cockpit tracks. Shares closed at $152.43 on 18 Nov 2026.

Performance Over six months the shares gained 60.8%, against +25.1% for the median peer and -2.2% for the United States market (cap-weighted) — 3rd highest of 21 in its peer set.

Growth Revenue grew 4.6% over the last twelve months (peer median +5.0%); the operating margin is 16.4% (peer median 17.0%).

Valuation It trades at 26.2× forward earnings against a peer median of 21.9× (9th most expensive of 20).

Price implies For today's price to make sense, revenue must grow about 26% a year for seven years (Req g). Recent delivered growth is -5%, so the hurdle is +32 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.

Capital Return on invested capital runs 5.7 points below its cost of capital (9.8% WACC).

Credit Revvity has 4 bonds outstanding ($2.25B), rated BBB by the agencies and trading like BBB at a weighted spread of 91 bp.

Short interest Short interest is 5.8% of the free float (30 Oct 2026).

Next results Next results expected around 4 Feb 2027 (exchange calendar; dates can move).

Relative performance

10012515017521 May 202621 Aug 202618 Nov 2026RVTY 160Peer median 122
Six months, rebased to 100: Revvity against the median of its 20 peers (local-currency closes).

Revvity financials

Reported figures in USD; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
Revenue$2.94B$2.86B$2.76B$2.75B$3.31B
Revenue growth—+4%0%-17%—
Gross profit$1.45B$1.37B$1.32B$1.32B$1.76B
EBITDA$897M$833M$838M$831M$1.21B
Net income$253M$242M$296M-$118M$569M
Free cash flow$590M$507M$542M$9.90M$594M
Capital expenditure$65.4M$73.5M$86.6M$1.30B$85.6M
Total debt$2.77B$3.40B$3.33B$4.07B$4.60B

Quarterly statements and history in the cockpit →

Revvity competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

0%+20%+40%+60%0%+10%COLO-BZBHGHSOONSRT688271STMNGKOSLENSKARTBAX7733PENSN4543DIMBIMALGNCOOSTEAVTRRVTY6-month return →1-month return →
Up and to the right = strong over both horizons. Revvity is the large dot.

Fundamentals: revenue growth against valuation

0%+20%+40%0×50×100×150×COLO-BZBHSOONSRT688271STMNGKOSLENSKARTBAXPEN4543BIMRVTYRevenue growth (TTM) →Forward P/E →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Revvity is the large dot.

Capital: growth delivered against growth the price implies

0%+20%+40%0%20%40%COLO-BZBHSOONSRTSTMNLENSKARTBAX7733PENSN4543DIMBIMAVTRRVTYGrowth delivered (Del g) →Growth the price implies (Req g, 7 yrs) →
Above the diagonal = the price needs more growth than the company has been delivering; below = the price already allows for a slowdown. Revvity is the large dot.

Revvity competitors and peer comparison

Head to head with its named competitors (RVTY vs TMO vs DHR vs BIO)
CompanyMarket cap6M returnRevenue growthOp. marginForward P/EReq g
Revvity RVTY$17.0B+61%+5%16%26.2×26.4%
Thermo Fisher Scientific TMO$257B+53%+8%19%25.7×21.3%
Danaher DHR$161B+34%+6%21%25.1×20.8%
Bio-Rad Laboratories BIO$10.1B+29%+1%9%34.6×26.0%

How Revvity compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Revvity against its 20 peers (data as of 18 Nov 2026)
MeasureRVTYPeer medianRank in peer set
1-month return-2.3%+6.3%3rd lowest of 21
6-month return+60.8%+25.1%3rd highest of 21
Distance from 52-week high-11.2%-11.7%10th highest of 21
Revenue growth (TTM)+4.6%+5.0%10th lowest of 21
Operating margin16.4%17.0%10th lowest of 21
Forward P/E26.2×21.9×9th most expensive of 20
Growth the price implies (Req g, 7 yrs)26.4%13.1%4th most demanding of 18
Growth delivered (Del g)-5.5%+8.7%lowest of 18
Hurdle (Req g minus delivered)+31.8 pp+3.4 ppmost demanding of 18
ROIC minus cost of capital-5.7 pp+0.6 pp3rd lowest of 21
EV / EBITDA21.4×12.2×5th most expensive of 18
Net debt / EBITDA2.4×1.0×5th most indebted of 18
Bond spread91 bp108 bp3rd tightest of 9

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginForward P/EReq gDelivered g
Revvity RVTYUnited States$17.0B+61%+5%16%26.2×26.4%-5.5%
Coloplast A/S COLO-B.CODenmark$16.6B+24%+4%25%20.0×-2.1%+8.3%
Zimmer Biomet ZBHUnited States$19.6B+21%+7%16%11.7×7.4%+3.2%
Guardant Health GHUnited States$19.6B+26%+42%-39%n/an/an/a
Sonova SOON.SWSwitzerland$19.8B+40%-6%23%25.3×6.0%+6.7%
Sartorius SRT.DEGermany$19.9B+26%+4%18%43.0×25.6%+8.7%
Shanghai United Imaging Healthcare 688271.SSChina$14.4B+4%+27%9%45.7×n/an/a
Straumann STMN.SWSwitzerland$20.4B+20%+2%21%32.9×16.2%+12.8%
Glaukos GKOSUnited States$13.8B+62%+47%-9%161.5×n/an/a
Lenskart Solutions LENSKART.NSIndia$13.6B+49%+35%10%137.7×53.2%+33.5%
Baxter International BAXUnited States$13.5B+39%+5%6%12.7×13.4%-0.7%
Olympus 7733.TJapan$12.7B+5%+9%18%18.7×-6.5%+6.7%
Penumbra PENUnited States$12.6B-2%+17%12%55.7×30.7%+20.2%
Smith & Nephew SN..LUnited Kingdom$12.6B+1%+2%17%14.2×11.1%+5.6%
Terumo 4543.TJapan$24.0B+32%+15%17%27.8×8.8%+13.0%
Sartorius Stedim Biotech DIM.PAFrance$24.2B+32%+4%19%45.7×33.4%+9.2%
bioMerieux BIM.PAFrance$11.8B+26%-3%15%20.2×8.6%+5.5%
Align Technology ALGNUnited States$11.6B0%+4%19%13.8×13.1%+10.3%
Cooper Companies (The) COOUnited States$11.6B-2%+5%19%13.4×9.4%+11.0%
Steris STEUnited States$25.2B+21%+8%20%21.9×14.0%+13.8%
Avantor AVTRUnited States$10.4B+95%+1%8%17.5×16.4%+0.5%

Revvity bonds and credit

Revvity has 4 bonds outstanding with $2.25B face value. The agencies rate it BBB; its bonds trade like BBB. Weighted yield 5.64%, a spread of 91 bp over government bonds.

Every bond, yield and spread in the cockpit →

Questions

Who are Revvity's main competitors?
Named competitors: Thermo Fisher Scientific (TMO), Danaher Corporation (DHR), Bio-Rad Laboratories (BIO). The cockpit's measured peer set (industry) also includes Coloplast A/S (COLO-B.CO), Zimmer Biomet (ZBH), Guardant Health (GH), Sonova (SOON.SW), Sartorius (SRT.DE), Shanghai United Imaging Healthcare (688271.SS).
Is Revvity expensive compared with its peers?
On forward p/e it trades at 26.2× against a peer median of 21.9×, 9th most expensive of 20 in its peer set. For today's price to make sense, revenue must grow about 26% a year for seven years (Req g). Recent delivered growth is -5%, so the hurdle is +32 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.
How has Revvity stock performed?
Over six months to 18 Nov 2026 the shares returned +60.8% against +25.1% for the median peer; over one year +67.6%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.